Immunohistochemistry - Research News and Information

Saturday, January 10, 2009

HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.

29 Nov 2008 Toward the development of a novel cancer immunotherapy, we have previously identified several tumor-associated antigens (TAAs) and the epitopes recognized by human histocompatibility leukocyte (HLA)-A2/A24-restricted cytotoxic T lymphocyte (CTL). ... Read more...

Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin.

29 Nov 2008 Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) represent the 2 most common types of nonmelanoma skin cancer. Both derive from keratinocytes but show a distinct biological behavior. Here we present transcriptional profiling data of a ... Read more...

Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis.

29 Nov 2008 The aim of our study was to analyze the alterations of some candidate tumor suppressor genes (TSGs) viz. LIMD1, LTF, CDC25A, SCOTIN, RASSF1A and CACNA2D2 located in the chromosomal region 3p21.31 associated with the development of early dysplastic ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Immunohistochemistry'

These are the very latest articles for this heading:

• HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. 29 Nov 2008
• Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. 29 Nov 2008
• Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis. 29 Nov 2008
• Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. 29 Nov 2008
• Primary cutaneous B-cell lymphoma in a child. 29 Nov 2008
• Central and peripheral pathology of kuru: pathological analysis of a recent case and comparison with other forms of human prion disease. 25 Nov 2008
• Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphoma. 13 Nov 2008
• Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. 13 Nov 2008
• Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. 13 Nov 2008
• KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer. 13 Nov 2008
• MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. 13 Nov 2008
• Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival. 13 Nov 2008
• Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. 13 Nov 2008
• Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. 13 Nov 2008
• Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. 13 Nov 2008
• Peripheral nerve pericytes originating from the blood-nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells. 30 Oct 2008
• Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer. 30 Oct 2008
• High expression of human nonmetastatic clone 23 type 1 in cancer of uterine cervix and its association with poor cell differentiation and worse overall survival. 30 Oct 2008
• An infant with giant juvenile xanthogranuloma presenting as an axillary mass. 30 Oct 2008
• Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. 30 Oct 2008

See a longer list of these articles.

Technical information about 'Immunohistochemistry'

Definition: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.

Descriptor UI: D007150

Alternative terms: Immunohistochemistry; Immunolabeling Techniques; Immunolabeling Technique; Technique, Immunolabeling; Techniques, Immunolabeling; Immunolabeling Technics; Immunolabeling Technic; Technic, Immunolabeling; Technics, Immunolabeling; Immunogold Techniques; Immunogold Technique; Technique, Immunogold; Techniques, Immunogold; Immunogold Technics; Immunogold Technic; Technic, Immunogold; Technics, Immunogold; Immunohistocytochemistry; Immunogold-Silver Techniques; Immunogold Silver Techniques; Immunogold-Silver Technique; Technique, Immunogold-Silver; Techniques, Immunogold-Silver; Immunogold-Silver Technics; Immunogold Silver Technics; Immunogold-Silver Technic; Technic, Immunogold-Silver; Technics, Immunogold-Silver; Immunocytochemistry;

Allowable Qualifiers: history; instrumentation; methods; standards; trends; utilization; veterinary; statistics & numerical data; ethics; classification; economics;

Tree Number: E01.450.495.435; E05.200.500.607.512; E05.200.750.551.512; E05.478.594.430; H01.158.100.656.234.512; H01.158.201.344.512; H01.158.201.486.512; H01.181.122.573.512; H01.181.122.605.512;

History Note: 88

Technical Notes: GEN; avoid as coord; SPEC qualif when IM; no qualif when NIM; immunohistochem of disease is disease /diag or /metab